Bronnen:
- Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: Latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6:229-39.,Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28 (Supplement 8): viii61-viii65.,Chen Y, Du H. The promising PARP inhibitors in ovarian cancer therapy. From Olaparib to others. Biomed Pharmacother. 2018;99:552-60. ,Cancer Genomic Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-15.,Fong PC, Boss DS, Yap TA et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-34.,Markman M. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer. Women’s Health. 2018;14:1-6.,Matulonis UA, Penson RT, Domchel SM, et al. Olaparib monotherapy in patientsd with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol. 2016;27:1013-9.,Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomisedf, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17:1579-89.,Dal Molin GZ, Westin SN and Coleman RL. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncol. 2018;10.2217/fon-2018-0215 [Epub ahead of print],Coleman RL, Oza AM, Lorusso D, et al. Rucaparib for maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIE3): a randomized, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2018;390:1949-61.,Essel KG & Moore KN. Niraparib for the treatment of ovarian cancer. Expert Rev Anticancer Ther. DOI: 10.1080/14737140.2018.1490180.,Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenancew therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154-64.,Ledermann JA. Front-line therapy of advanced ovarian cancer: new approaches. Ann Oncol 2017: 28 (Suppl. 8): viii46-viii50.